Evolocumab for Patients Without Known Atherosclerosis and With Diabetes This prespecified subgroup analysis of the VESALIUS-CV multinational randomized clinical trial assesses whether evolocumab could prevent a first major cardiovascular event in adult patients without kn...

En pacientes de alto riesgo sin aterosclerosis significativa conocida con diabetes, evolocumab reduce el riesgo de un primer evento CV mayor #evolocumab #diabetes #atherosclerosis jamanetwork.com/journals/jam...

Evolocumab for Reducing MACE, Lead Exposure and CVD, AI Scribes for Clinicians, and more Editor’s Summary by Linda Brubaker, MD, Preeti Malani, MD, MSJ, Deputy Editors of JAMA, and Gregory Curfman, MD, Executive Editor of the Journal of the American Medical Association, for articles published from March 28-April 3, 2026.

JAMA Deputy Editors Linda Brubaker, MD, and Preeti Malani, MD, MSJ, and Executive Editor Gregory Curfman, MD, discuss the latest science published in JAMA:

➡️ #Evolocumab for Reducing MACE,
➡️ #Lead Exposure and #CVD, and more.

ja.ma/41JePfE

Evolocumab for Patients Without Known Atherosclerosis and With Diabetes This prespecified subgroup analysis of the VESALIUS-CV multinational randomized clinical trial assesses whether evolocumab could prevent a first major cardiovascular event in adult patients without kn...

En pacientes de alto riesgo sin aterosclerosis significativa conocida y con diabetes, evolocumab reduce el riesgo de un primer evento CV mayor #evolocumab #atherosclerosis #diabetes jamanetwork.com/journals/jam...

Evolocumab's Impact on Coronary Physiology on JHLT: The Podcast The JHLT team discusses a study from Aarhus University Hospital in Denmark on the impact evolocumab may have on coronary physiology and microstructure in de-novo heart transplant recipients.

On today's #JHLT podcast, Salma Karim and Hans Eiskjær of @au.dk Hospital join early career guest host Bin Yang of Mass General in Boston to discuss the impact of #evolocumab on coronary physiology and microstructure in heart transplant.

#cardiosky #transplantsky #medsky

LDL-Anstieg unter Evolocumab | arznei-telegramm Das arznei-telegramm informiert - unabhängig. kritisch. anzeigenfrei.

#LDL-Anstieg unter #Evolocumab

Zwei Fallberichte schildern paradoxe Reaktionen unter dem PCSK9-Inhibitor.
www.arznei-telegramm.com/de/6439/ldl-...

Evolocumab (REPATHA) ohne vorherigen Herzinfarkt oder Schlaganfall? | arznei-telegramm Das arznei-telegramm informiert - unabhängig. kritisch. anzeigenfrei.

#Evolocumab (REPATHA) ohne vorherigen Herzinfarkt oder Schlaganfall?

Der teure PCSK9-Hemmer wurde in dieser bislang nicht zugelassenen Indikation in der VESALIUS-CV-Studie geprüft.
www.arznei-telegramm.com/de/6431/evol...

Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition: A Prespecified Analysis From FOURIER

In #FOURIER, MACE risk ↑ by 11% for every +5 BMI above 30; this excess risk was substantially attenuated by the PCSK9i #evolocumab, underscoring the need to address residual CVD risk in #obesity through intensive #LDL-C ↓ & calls for condition-specific recommendations.
www.jacc.org/doi/10.1016/...

American Diabetes Association American Diabetes Association

FOURIER data on the benefit of #PCSK9i #evolocumab in adults with #T1D are now cited in the 2026 @AmDiabetesAssn
Standards of Care—an important step in an area w/ very limited evidence to guide intensive #LDL-C lowering in T1D.

diabetesjournals.org/care/article...

Evolocumab in Patients without a Previous Myocardial Infarction or Stroke | NEJM The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, s...

Evolocumab reduce el riesgo del primer evento CV en pacientes con aterosclerosis o diabetes sin un IM o ictus previo #evolocumab #MACE #PrimaryPrevention www.nejm.org/doi/pdf/10.1...

Evolocumab shows clear benefit in preventing first-time heart attacks and strokes Adding the PCSK9 inhibitor evolocumab to standard lipid-lowering therapy significantly reduced first major cardiovascular events in adults with atherosclerosis or high-risk diabetes who had never had ...

A breakthrough study: starting evolocumab early can prevent first heart attacks and strokes. Powerful support for aggressive LDL cholesterol lowering in high-risk patients! 💉🫀 www.news-medical.net/news/2025111... #Evolocumab #Heart #Cardiology @nejm.org

LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that Repatha®...

🚀 Big win for #ASCVD Prevention!
The VESALIUS-CV Phase 3 trial fullfilled its primary endpoints: #evolocumab significantly reduced CVD events in high-risk patients without prior AMI or stroke. 💥💓
This is a major leap forward for primary prevention!
zurl.co/SPJSp

The PCSK9 inhibitor #evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of #cardiovascular disease.

How Cholesterol Drug May Prevent Heart Attacks A new study conducted at Cedars-Sinai reveals how the cholesterol-reducing drug evolocumab prevents heart attacks in people with coronary artery disease—a leading cause of death in the United States.C...

Exciting news in heart health! A recent study found that 18 months of #evolocumab treatment led to a shift toward lower-risk plaque in heart arteries & reduced microcalcification activity, without significant change in total plaque volume.
#CardioSky
www.cedars-sinai.org/newsroom/res...

Long-Term Lipid Lowering With #Evolocumab in Older Individuals

#CardioSky #cvPrev #JACC
www.jacc.org/doi/10.1016/...
@jaccjournals.bsky.social @erinmichos.bsky.social @michaeldshapiro.bsky.social @drlipid.bsky.social @psatishmd.bsky.social @anastasiasmihaili.bsky.social @vassv.bsky.social